DK1299727T3 - Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper - Google Patents

Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper

Info

Publication number: DK1299727T3
Authority: DK; Denmark
Prior art keywords: prss2; lung; compositions; bladder; diagnosis
Prior art date: 2000-07-12

Application number

DK01984181T

Other languages

English (en)

Inventor

Arthur B Raitano

Aya Jakobovits

Mary Faris

Pia M Challita-Eid

Douglas Saferran

Rene S Hubert

Original Assignee

Agensys Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-12

Filing date

2001-07-12

Publication date

2009-06-15

2000-07-12 Priority claimed from US09/615,285 external-priority patent/US7037667B1/en

2001-07-12 Application filed by Agensys Inc filed Critical Agensys Inc

2009-06-15 Application granted granted Critical

2009-06-15 Publication of DK1299727T3 publication Critical patent/DK1299727T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Hematology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Zoology (AREA)
Urology & Nephrology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physical Education & Sports Medicine (AREA)
Pathology (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Ophthalmology & Optometry (AREA)
Biochemistry (AREA)
Analytical Chemistry (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Cell Biology (AREA)
Endocrinology (AREA)

DK01984181T 2000-07-12 2001-07-12 Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper DK1299727T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/615,285 US7037667B1 (en)	1998-06-01	2000-07-12	Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
PCT/US2001/022168 WO2002004953A2 (en)	2000-07-12	2001-07-12	Novel tumor antigen useful in diagnosis and therapy of bladder, ovary, lung and kidney cancers

Publications (1)

Publication Number	Publication Date
DK1299727T3 true DK1299727T3 (da)	2009-06-15

Family

ID=24464750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01984181T DK1299727T3 (da)	2000-07-12	2001-07-12	Hidtil ukendt tumorantigen, der er egnet til diagnosticering og behandling af blære-, ovarie-, lunge-, og nyrecancertyper

Country Status (11)

Country	Link
EP (2)	EP2075582A3 (da)
JP (2)	JP2004511219A (da)
AT (1)	ATE429643T1 (da)
AU (1)	AU2002218786A1 (da)
CA (1)	CA2415923C (da)
CY (1)	CY1109254T1 (da)
DE (1)	DE60138465D1 (da)
DK (1)	DK1299727T3 (da)
ES (1)	ES2323407T3 (da)
PT (1)	PT1299727E (da)
WO (1)	WO2002004953A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7037667B1 (en)	1998-06-01	2006-05-02	Agensys, Inc.	Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
WO2004097034A2 (en) *	2003-05-02	2004-11-11	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 4 (tmprss4)
WO2004097358A2 (en) *	2003-05-02	2004-11-11	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with human transmembrane serine protease 2 (tmprss2)
RS61825B1 (sr)	2018-01-26	2021-06-30	Regeneron Pharma	Anti-tmprss2 antitela i fragmenti koji vezuju antigen
WO2021163076A1 (en)	2020-02-10	2021-08-19	Regeneron Pharmaceuticals, Inc.	ANTl-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2024252183A1 (en) *	2023-06-08	2024-12-12	Institut Pasteur	Single domain antibodies directed against human transmembrane- serine protease 2 (tmprss2)

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US4870009A (en)	1982-11-22	1989-09-26	The Salk Institute For Biological Studies	Method of obtaining gene product through the generation of transgenic animals
US4736866B1 (en)	1984-06-22	1988-04-12		Transgenic non-human mammals
US5225538A (en)	1989-02-23	1993-07-06	Genentech, Inc.	Lymphocyte homing receptor/immunoglobulin fusion proteins
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
EP0489149B1 (en)	1990-06-27	2001-10-17	Princeton University	Probes for detecting mutant p53
SE9002480D0 (sv)	1990-07-23	1990-07-23	Hans Lilja	Assay of free and complexed prostate-specific antigen
AU2147192A (en)	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
US5733731A (en)	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
US5674682A (en)	1992-10-29	1997-10-07	Thomas Jefferson University	Nucleic acid primers for detecting micrometastasis of prostate cancer
US5837501A (en)	1993-07-09	1998-11-17	Akzo Nobel N.V.	Nucleic acid quantitation by co-amplification of target with multiple internal controls
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
CH686982A5 (fr)	1993-12-16	1996-08-15	Maurice Stroun	Méthode pour le diagnostic de cancers.
US5599677A (en)	1993-12-29	1997-02-04	Abbott Laboratories	Immunoassays for prostate specific antigen
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
US5837682A (en)	1996-03-08	1998-11-17	The Children's Medical Center Corporation	Angiostatin fragments and method of use
WO1996002561A1 (en)	1994-07-20	1996-02-01	The General Hospital Corporation	Interaction trap systems for detecting protein interactions
GB9506466D0 (en)	1994-08-26	1995-05-17	Prolifix Ltd	Cell cycle regulated repressor and dna element
US5919652A (en)	1994-11-09	1999-07-06	The Regents Of The University Of California	Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
US5736524A (en)	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US6071890A (en)	1994-12-09	2000-06-06	Genzyme Corporation	Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
US5614372A (en)	1995-02-24	1997-03-25	Lilja; Hans	Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5792453A (en)	1995-02-28	1998-08-11	The Regents Of The University Of California	Gene transfer-mediated angiogenesis therapy
US5962428A (en)	1995-03-30	1999-10-05	Apollon, Inc.	Compositions and methods for delivery of genetic material
WO1996032503A1 (en)	1995-04-11	1996-10-17	The General Hospital Corporation	Reverse two-hybrid systems
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
CU22559A1 (es)	1996-01-17	1999-05-03	Ct Ingenieria Genetica Biotech	Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
US5837680A (en)	1996-02-16	1998-11-17	Children's Medical Center Corporation	Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
ATE511849T1 (de)	1996-03-11	2011-06-15	Epimmune Inc	Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
AU706582B2 (en)	1996-03-25	1999-06-17	Juridical Foundation The Chemo-Sero-Therapeutic Research Institute	Angiogenic inhibitor containing tissue factor pathway inhibitor
ES2183166T3 (es)	1996-04-26	2003-03-16	Massachusetts Inst Technology	Ensayo de cribado por triple hibrido.
AU724077B2 (en)	1996-05-03	2000-09-14	Abbvie Inc.	Novel antiangiogenic peptides, polypeptides encoding same and methods for inhibiting angiogenesis
US5801146A (en)	1996-05-03	1998-09-01	Abbott Laboratories	Compound and method for inhibiting angiogenesis
JP2000516090A (ja)	1996-07-26	2000-12-05	スローン―ケッタリングインスティチュートフォーキャンサーリサーチ	遺伝子的免疫化のための方法と試薬
US5925523A (en)	1996-08-23	1999-07-20	President & Fellows Of Harvard College	Intraction trap assay, reagents and uses thereof
CA2271234C (en)	1996-10-15	2011-04-26	The Regents Of The University Of California	Animal models of human prostate cancer progression
US5846722A (en)	1996-10-16	1998-12-08	Terrapin Technologies, Inc.	System to detect small molecule/peptide interaction
US5840501A (en)	1996-10-25	1998-11-24	Bayer Corporation	Determination of cPSA
ATE387495T1 (de)	1996-12-03	2008-03-15	Amgen Fremont Inc	Vollkommen humane antikörper die egfr binden
US6043033A (en) *	1997-02-27	2000-03-28	Incyte Pharmaceuticals, Inc.	Human prostate-associated protease
US5972615A (en)	1998-01-21	1999-10-26	Urocor, Inc.	Biomarkers and targets for diagnosis, prognosis and management of prostate disease
IL139988A0 (en) *	1998-06-01	2002-02-10	Urogenesys Inc	Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
US6166194A (en)	1998-06-29	2000-12-26	Myriad Genetics, Inc.	TMPRSS2 is a tumor suppressor
CA2341142A1 (en) *	1998-09-02	2000-03-09	Diadexus Llc	A novel method of diagnosing, monitoring, staging, imaging and treating various cancers
EP1117836A2 (en) *	1998-09-30	2001-07-25	Millennium Pharmaceuticals, Inc.	Expressionanalysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
EP1131095A4 (en) *	1998-10-19	2003-04-23	Diadexus Inc	METHOD FOR DIAGNOSING, MONITORING, CLASSIFYING STAGES, VISUALIZING AND TREATING PROSTATE CANCER

2001
- 2001-07-12 AT AT01984181T patent/ATE429643T1/de active
- 2001-07-12 EP EP09002403A patent/EP2075582A3/en not_active Withdrawn
- 2001-07-12 WO PCT/US2001/022168 patent/WO2002004953A2/en active Application Filing
- 2001-07-12 PT PT01984181T patent/PT1299727E/pt unknown
- 2001-07-12 CA CA2415923A patent/CA2415923C/en not_active Expired - Fee Related
- 2001-07-12 AU AU2002218786A patent/AU2002218786A1/en not_active Abandoned
- 2001-07-12 EP EP01984181A patent/EP1299727B1/en not_active Expired - Lifetime
- 2001-07-12 JP JP2002509772A patent/JP2004511219A/ja not_active Withdrawn
- 2001-07-12 ES ES01984181T patent/ES2323407T3/es not_active Expired - Lifetime
- 2001-07-12 DK DK01984181T patent/DK1299727T3/da active
- 2001-07-12 DE DE60138465T patent/DE60138465D1/de not_active Expired - Lifetime
2008
- 2008-12-25 JP JP2008329870A patent/JP2009148264A/ja active Pending
2009
- 2009-07-14 CY CY20091100753T patent/CY1109254T1/el unknown

Also Published As

Publication number	Publication date
AU2002218786A1 (en)	2002-01-21
JP2009148264A (ja)	2009-07-09
DE60138465D1 (de)	2009-06-04
EP1299727B1 (en)	2009-04-22
CA2415923C (en)	2011-10-25
ES2323407T3 (es)	2009-07-15
WO2002004953A2 (en)	2002-01-17
WO2002004953A3 (en)	2002-09-19
EP1299727A2 (en)	2003-04-09
EP2075582A2 (en)	2009-07-01
EP2075582A3 (en)	2010-01-06
JP2004511219A (ja)	2004-04-15
CA2415923A1 (en)	2002-01-17
PT1299727E (pt)	2009-07-09
WO2002004953A8 (en)	2002-07-04
ATE429643T1 (de)	2009-05-15
CY1109254T1 (el)	2014-07-02

Publication	Publication Date	Title
CY1111906T1 (el)	2015-11-04	Αντιγονο ογκων χρησιμο για τη διαγνωση και θεραπεια καρκινου του προστατη και του παχεος εντερου
ATE207958T1 (de)	2001-11-15	Äusserliche domäne von c-erbb-2:gp75
EP2060630A3 (en)	2010-04-14	PCA3, PCA3 genes, and methods of use
ATE549347T1 (de)	2012-03-15	Gene von säugetiere, und damit verbundene reagentien, methoden
ATE516304T1 (de)	2011-07-15	Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
BR9809443A (pt)	2000-06-13	Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão.
NO308310B1 (no)	2000-08-28	Hovedsakelig rent KGF protein og dets anvendelse
WO2004033631A8 (en)	2005-04-28	Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
CY1113153T1 (el)	2016-04-13	ΙL-1β ΔΕΣΜΕΥΤΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΚΑΙ ΘΡΑΥΣΜΑΤΑ ΑΥΤΩΝ
Murphy et al.	2008	Odontogenic ameloblast-associated protein nature of the amyloid found in calcifying epithelial odontogenic tumors and unerupted tooth follicles
DE69117949D1 (de)	1996-04-18	Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
CY1109254T1 (el)	2014-07-02	Νεο αντιγονο ογκου χρησιμο στη διαγνωση και θεραπεια καρκινων της ουροδοχου κυστης, των ωοθηκων, του πνευμονα και του νεφρου
DE602005026931D1 (de)	2011-04-28	Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik
ES2079621T3 (es)	1996-01-16	Procedimiento de identificacion o de titulacion de proteinas y aplicaciones.
DE60026733D1 (de)	2006-05-11	Histone-deacetylase-8 proteine, nukleinsäuren und methoden zur verwendung
WO2005019831B1 (en)	2005-11-03	Methods for reducing complexity of a sample using small epitope antibodies
ATE363070T1 (de)	2007-06-15	Auswertung von biologischen mitteln in lebenden zielzellen
EA200000845A1 (ru)	2001-08-27	Ген, кодирующий новый маркер рака
DK0833948T3 (da)	2006-05-08	Tyktarmspecifikt gen og protein
ATE418604T1 (de)	2009-01-15	Gegen das prothrombin-fragment f1+2 gerichtete antikörper, ihre herstellung und verwendung
Fukamachi et al.	2009	An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas
FR2795414B1 (fr)	2002-07-05	Polypeptide icbp90 et ses fragments et polynucleotides codant lesdits polypeptides et applications au diagnostic et au traitement du cancer
ATE409746T1 (de)	2008-10-15	Neuer spannungsabhängiger kaliumkanal und seine verwendung zur entwicklung von therapeutika
AU768688B2 (en)	2003-12-18	Protein markers for lung cancer and use thereof
TH62170A (th)	2004-05-20	วัคซีนเชื้อก่อโรค Lawsonia intracellularis